Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (Q36680024)
Jump to navigation
Jump to search
scientific article published on March 2013
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial |
scientific article published on March 2013 |
Statements
1 reference
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial (English)
1 reference
Christina Davies
1 reference
Hongchao Pan
1 reference
Jon Godwin
1 reference
Vinod Raina
1 reference
Mirta Abraham
1 reference
Victor Hugo Medeiros Alencar
1 reference
Atef Badran
1 reference
Xavier Bonfill
1 reference
Joan Bradbury
1 reference
Michael Clarke
1 reference
Rory Collins
1 reference
Antonella Delmestri
1 reference
John F Forbes
1 reference
Peiman Haddad
1 reference
Ming-Feng Hou
1 reference
Moshe Inbar
1 reference
Hussein Khaled
1 reference
Joanna Kielanowska
1 reference
Wing-Hong Kwan
1 reference
Beela S Mathew
1 reference
Indraneel Mittra
1 reference
Bettina Müller
1 reference
Antonio Nicolucci
1 reference
Octavio Peralta
1 reference
Fany Pernas
1 reference
Ramachandran Radhika
1 reference
Balakrishnan Rajan
1 reference
Maryna T Rubach
1 reference
Sera Tort
1 reference
Yaochen Wang
1 reference
Richard Peto
1 reference
Adjuvant Tamoxifen: Longer Against Shorter (ATLAS) Collaborative Group
1 reference
Identifiers
1 reference